Using our molecular characterization methods in clinically relevant cell lines we analyzed how combined XPO1 targeting affects PGC1α level, therapy responsiveness, ERα signaling and tumor outcome, thereby evaluating the potential of its inhibition as a means to prevent metastatic tumor adaptation and therapy resistance. This evidence concerns the gene PPARGC1A and neoplasm.